[HTML][HTML] SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast-derived
mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
…, H Muramatsu, C Bajusz, W Rijnink… - Proceedings of the …, 2022 - National Acad Sciences
Combined vaccine formulations targeting not only hemagglutinin but also other influenza virus
antigens could form the basis for a universal influenza virus vaccine that has the potential …
antigens could form the basis for a universal influenza virus vaccine that has the potential …
[HTML][HTML] Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
…, J Tan, C Bajusz, H Muramatsu, W Rijnink… - Nature …, 2022 - nature.com
Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high
capacity for rapid development. Generation of a universal influenza virus vaccine with the …
capacity for rapid development. Generation of a universal influenza virus vaccine with the …
[HTML][HTML] B-cells and antibodies as contributors to effector immune responses in tuberculosis
WF Rijnink, THM Ottenhoff, SA Joosten - Frontiers in immunology, 2021 - frontiersin.org
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is still a major threat to
mankind, urgently requiring improved vaccination and therapeutic strategies to reduce TB-…
mankind, urgently requiring improved vaccination and therapeutic strategies to reduce TB-…
[HTML][HTML] The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses
WF Rijnink, D Stadlbauer, E Puente-Massaguer… - Journal of …, 2023 - Am Soc Microbiol
Improved broad-spectrum influenza virus vaccines are desperately needed to provide
protection against both drifted seasonal and emerging pandemic influenza A viruses (IAVs). …
protection against both drifted seasonal and emerging pandemic influenza A viruses (IAVs). …
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD (preprint)
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast
derived mAbs from subjects who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
derived mAbs from subjects who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
Learning from pre-pandemic data to forecast viral antibody escape
S Gurev - 2023 - dspace.mit.edu
Effective pandemic preparedness relies on anticipating viral mutations that are able to evade
host immune responses in order to facilitate vaccine and therapeutic design. However, …
host immune responses in order to facilitate vaccine and therapeutic design. However, …
In depth characterization of immune response against the spike protein of Sars-CoV-2 in response to infection and mRna vaccination
F Amanat - 2021 - search.proquest.com
Severe acute respiratory syndrome 2 (SARS-CoV-2) first emerged in the city of Wuhan in
the province of Hubei in China in late 2019. Infection with SARS-CoV-2 leads to coronavirus …
the province of Hubei in China in late 2019. Infection with SARS-CoV-2 leads to coronavirus …
